Blowback: Consequences of evaluation for evaluation

American Journal of Evaluation

Volumn 29, Issue 4, 2008, Pages 416-426

  House, Ernest R ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Bias; Drug evaluation; Politics; Randomized trials

Indexed keywords

EID: 56349103320     PISSN: 10982140     EISSN: 15570878     Source Type: Journal    
DOI: 10.1177/1098214008322640     Document Type: Article

References (27)

1. Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. (2003). Association of funding and conclusions in randomized drug trials. Journal of the American Medical Association, 290, 921.
2. Angell, M. (2004). The truth about the drug companies. New York: Random House.
3. Armstrong, D. (2006, May 15). How the New England Journal missed warning signs on Vioxx. Wall Street Journal, pp. A1-2.
4. Berenson, A. (2006a, May 13). Follow-up study on Vioxx safety is disputed. New York Times, p. B3.
5. Berenson, A. (2006 b, May 31). Merck admits a data error on Vioxx. New York Times, p. C1-2.
6. Bodenheimer, T. (2000). Uneasy alliance: Clinical investigators and the pharmaceutical industry. New England Journal of Medicine, 342, 1539-1544.
7. Braudel, F. (1981, 1982, 1984). Civilization and capitalism: 15th to the 18th centuries (3 vols.). New York: Harper and Row.
8. Campbell, D.T., & Stanley, J.C. (1963). Experimental and quasi-experimental designs for research. Chicago: Rand McNally.
9. Committee on the Assessment of the U.S. Drug Safety System. (2006). A. Baciu, K. Stratton, & S. P. Burke (Eds.), The future of drug safety: Promoting and protecting the health of the public. Washington, DC: Institute of Medicine, National Academies.
10. Garattini, S., Bertele, V., & Bassi, L.L. (2003, May 31). How can research ethics committees protect patients better ? British Medical Journal, 326, 1199-1201.
11. Gilpin, R. (1987). The political economy of international relations. Princeton, NJ: Princeton University Press.
12. Glanz, J. (2004, February 18). Scientists accuse White House of distorting facts. New York Times, pp. D1-2.
13. Harris, G. (2006, September 29). F.D.A. says Bayer failed to reveal drug risk study. New York Times. pp. A1, A9.
14. House, E.R. (1993). Professional evaluation. Thousand Oaks, CA: Sage.
15. Lexchin, J., Bero, L.A., Djulbegovic, B., & Clark, O. (2003, May 31). Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. British Medical Journal, 326, 1167-1170.
16. Mathews, A.W. (2005, May 10). Worrisome ailment in medicine: Misleading journal articles. Wall Street Journal, pp. A1-2.
17. Mathews, A.W. (2006, September 1). Drug firms use financial clout to push industry agenda at FDA. Wall Street Journal, pp. A1-2.
18. Mayor, S. (2003, May 31). World Medical Association reviews doctors' links with drug companies. British Medical Journal, 326, 1165.
19. Melander, H., Ahlqvist-Rastad, J., Meijer, G., & Beermann, B. (2003, May 31). Evidence b(i)ased medicine- selective reporting from studies sponsored by pharmaceutical industry: Review of studies in new drug applications. British Medical Journal, 326, 1171-1173.
20. Moynihan, R. (2003 a, May 31). Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: Entanglement. British Medical Journal, 326, 1189-1192.
21. Moynihan, R. (2003 b, May 31). Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. British Medical Journal, 326, 1193-1196.
22. Pear, R. (2004, February 22). Taking spin out of report that made bad into good health. New York Times, pp. D1-2.
23. Pollack, A. (2006, September 12). Stanford to ban drug makers' gifts to doctors, even pens. New York Times, p. C2.
24. Pollack, A., & Abelson, R. (2006, May 22). Why the data diverge on the dangers of Vioxx. New York Times, pp. C1, 5.
25. Ryan, A. (2004). Foreword to E. R. House: The role of the evaluator in a political world. Canadian Journal of Program Evaluation, 19(2), 1-16.
26. Wolfe, A. (2006, July/August). Why conservatives can't govern. Washington Monthly, pp. 15-16.
27. Zimmerman, R., & Tomsho, R. (2005, May 26). Medical editor turns activist on drug trials. Wall Street Journal, pp. B1-2.